Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet Respiratory Medicine

Topics

Medicine

Pathology

Internal Medicine

Pulmonary And Respiratory Medicine

Cardiology And Cardiovascular Medicine

Show all topics

DOI

10.1016/s2213-2600(17)30305-3